Attralus Stock

attralus.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $198.55MM

Attralus is a biopharmaceutical company focused on creating medicines to improve the lives of patients with systemic amyloidosis. The company uses pan-amyloid removal (PAR) therapeutics to bind and remove toxic amyloid in organs and tissues.

Register To Buy and Sell Shares

For more details on financing and valuation for Attralus, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Attralus’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Attralus.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Mark Timney
Chief Executive Officer
Gregory Bell MD
Chief Medical Officer
Glen Firestone
Chief Business Officer
Spencer Guthrie
Co-Founder & Chief Operating Officer
Krishna Gorti MD
Head of Corporate Development
James Testa
Vice President, Finance
Christine Huh
Head of Human Resources
Jonathan Wall Ph.D
Co-Founder & Interim Chief Scientific Officer
Michael L. Klein Ph.D
Senior Vice President, Chemistry, Manufacturing, and Controls

Board Members

Alexander Denner Ph.D
Sarissa Capital Management
Corey Goodman Ph.D
Richard Gaster Ph.D

Frequently Asked Questions About Attralus’ Stock

Can you buy Attralus’ stock?
Attralus is not publicly traded on NYSE or NASDAQ in the U.S. To buy Attralus’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Attralus’ stock?
Yes, you can sell stock of a private company like Attralus. Forge can help you sell your Attralus stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Attralus’ stock price?
Attralus is a privately held company and therefore does not have a public stock price. However, you may access Attralus’ private market stock price with Forge Data.
What is Attralus’ stock ticker symbol?
Attralus does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Attralus Closes $56 Million Financing
Attralus, Inc., a clinical-stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that it has closed a $56 million financing. The financing round was led by new investor Alpha Wave Ventures and also included Bristol Myers Squibb (BMY). Existing investors also participated including founding investor venBio Partners, Surveyor Capital (a Citadel company), Vivo Capital, Logos Capital and Sarissa Capital Management.
Updated on: Jun 14, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.